- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03517618
TS-1 in Combination With Calcium Folinate in Patients With Heavily Pre-treated mCRC
A Phase II Study Assessing Efficacy and Safety of TS-1 in Combination With Calcium Folinate in Patients With Heavily Pre-treated Metastatic Colorectal Cancer
Primary Objective:
To determine disease control rate (DCR) of TS-1® in patients with heavily pre-treated metastatic colorectal cancer
Secondary Objectives:
- To determine objective response rate (ORR)
- To determine time to progression (TTP)
- To determine overall survival (OS)
- To assess incidence of adverse events (AEs), serious adverse events (SAEs) [Safety and Tolerability]
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Simon's optimal two-stage design will be used to determine the sample size for this study.
• Stage I: >1/9: The first 9 evaluable patients enrolled, >1 (or ≥2) responders are required in order to enter the second stage, otherwise the trial will be terminated at the first stage due to futility.
• Stage II: Total >8/34: For the total 34 evaluable patients, >8 (or ≥9) responders are required to conclude the effectiveness of the study regimen.
The primary endpoint will be disease control rate which will be presented in frequency tabulation with two-sided 95% confidence interval (using binomial estimation).
The secondary endpoints are described as follows:
- ORR will be presented in frequency tabulation with two-sided 95% confidence interval;
- TTP will be estimated by Kaplan-Meier method with two-sided 95% confidence interval;
- OS will be estimated by Kaplan-Meier method with two-sided 95% confidence interval;
- Incidence of adverse events (AEs), serious adverse events (SAEs) [Safety and Tolerability] : assessed by CTCAE v4.0. Safety parameters will only be analyzed on the safety analysis set and be presented in frequency tabulation.
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
-
Linkou, Taiwan
- Chang-Gung Memorial Hospital, Linkou
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- histologically or cytologically confirmed colorectal adenocarcinoma;
- metastatic and unresectable disease;
presence of at least one measurable tumor lesion which is defined as lesion that can be measured in at least one dimension (longest diameter) with a minimum size of:
- 10mm by CT scan and MRI (no less than double the slice thickness and a minimum of 10mm);
- 20mm by conventional techniques;
previously treatment to
- fluoropyrimidine, oxaliplatin and irinotecan;
- at least one targeted therapy
adequate hematopoietic function which is defined as below:
- hemoglobin ≥ 9 g/dL;
- absolute neutrophil count (ANC) ≥ 1,500/mm3;
- platelet count ≥ 100,000/mm3;
adequate hepatic function which is defined as below:
- total bilirubin ≤ 2 times upper limit of normal (ULN);
- hepatic transaminases (ALT and AST) ≤ 3 x ULN. If there are known liver metastases, ALT or AST must be ≤ 5 x ULN;
adequate renal function which is defined as below:
a. serum creatinine ≤ 1.5 x ULN;
- age of 20 years or above;
- ECOG performance status 0-2;
- life expectancy of at least 12 weeks;
- ability to take oral medication;
- ability to understand and willingness to sign a written informed consent document.
Exclusion Criteria:
- history or known presence of brain metastasis;
- presence of mental disease or psychotic manifestation;
- significant medical conditions that is contraindicated to study medication or render patient at high risk from treatment complications based on investigator's discretion;
- presence of diarrhea ≥ grade 2 in common terminology criteria for adverse event version 4.0 (CTCAE v4.0);
- other malignancy within the past 5 years (different site or histology) except for adequately treated basal or squamous cell skin cancer or cervical cancer in situ;
- recent (within 30 days prior to study treatment) treatment of another investigational drug;
- pregnant women or nursing mothers, or positive pregnancy test for women of childbearing potential. Patients with childbearing potential should have effective contraception for both the patient and his or her partner during the study.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: S-1 + leucovorin
Single arm
|
Eligible patients will receive TS-1 orally 40-60 mg (depending on patient's body surface area (BSA)) in combination with calcium folinate 30 mg twice a day for 7 days in a 2-week cycle. The treatment will be administered until disease progression, intolerable toxicity, or consent withdrawal during any time of the study.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Disease Control Rate (DCR)
Tidsramme: 6 months(an expected average)
|
Documented objective response (OR) (defined as partial response [PR] or complete response [CR]), assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 at any time during trial participation by Investigator assessment
|
6 months(an expected average)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Objective Response Rate (ORR)
Tidsramme: 6 months(an expected average)
|
the rate of completely response [CR] and partial response [PR] patients according to RECIST version 1.1.
criteria
|
6 months(an expected average)
|
Time to Progression (TTP)
Tidsramme: until disease progression, intolerable toxicity, 12 months(an expected average)
|
Participants follow-up for disease progression occur.
Maximum follow-up time is 12 months after the initial administration of the last subject
|
until disease progression, intolerable toxicity, 12 months(an expected average)
|
Overall survival (OS)
Tidsramme: at death or at the end of study, 24 months(an expected average)
|
median time between the start date of study treatment and the date of the death
|
at death or at the end of study, 24 months(an expected average)
|
Incidence of adverse events (AEs), serious adverse events (SAEs) [Safety and Tolerability]
Tidsramme: From the date of study entry until 30 days after the last dose of study treatment
|
assessed by the NCI-CTCAE (Common Toxicity Criteria for Adverse Effects) v4.0 and within some subgroups of patients
|
From the date of study entry until 30 days after the last dose of study treatment
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Hung-Chih Hsu, Chang Gung Memorial Hospital, Linkou, Taiwan
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Souglakos J, Androulakis N, Syrigos K, Polyzos A, Ziras N, Athanasiadis A, Kakolyris S, Tsousis S, Kouroussis Ch, Vamvakas L, Kalykaki A, Samonis G, Mavroudis D, Georgoulias V. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer. 2006 Mar 27;94(6):798-805. doi: 10.1038/sj.bjc.6603011.
- Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004 Apr 1;22(7):1209-14. doi: 10.1200/JCO.2004.11.037.
- Muratore A, Zorzi D, Bouzari H, Amisano M, Massucco P, Sperti E, Capussotti L. Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy? Ann Surg Oncol. 2007 Feb;14(2):766-70. doi: 10.1245/s10434-006-9146-1. Epub 2006 Nov 14.
- Van den Brande J, Schoffski P, Schellens JH, Roth AD, Duffaud F, Weigang-Kohler K, Reinke F, Wanders J, de Boer RF, Vermorken JB, Fumoleau P. EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer. Br J Cancer. 2003 Mar 10;88(5):648-53. doi: 10.1038/sj.bjc.6600781.
- Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crino L, Benedetti G, Evangelista W, Fanchini L, Cortesi E, Picone V, Vitello S, Chiara S, Granetto C, Porcile G, Fioretto L, Orlandini C, Andreuccetti M, Masi G; Gruppo Oncologico Nord Ovest. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007 May 1;25(13):1670-6. doi: 10.1200/JCO.2006.09.0928.
- Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouche O, Landi B, Louvet C, Andre T, Bibeau F, Diebold MD, Rougier P, Ducreux M, Tomasic G, Emile JF, Penault-Llorca F, Laurent-Puig P. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008 Jan 20;26(3):374-9. doi: 10.1200/JCO.2007.12.5906.
- Koizumi W, Boku N, Yamaguchi K, Miyata Y, Sawaki A, Kato T, Toh Y, Hyodo I, Nishina T, Furuhata T, Miyashita K, Okada Y. Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer. Ann Oncol. 2010 Apr;21(4):766-771. doi: 10.1093/annonc/mdp371. Epub 2009 Oct 14.
- Van Cutsem E, Nordlinger B, Adam R, Kohne CH, Pozzo C, Poston G, Ychou M, Rougier P; European Colorectal Metastases Treatment Group. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer. 2006 Sep;42(14):2212-21. doi: 10.1016/j.ejca.2006.04.012. Epub 2006 Aug 10.
- Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, Debraud F, Figer A, Grossmann J, Sawada N, Schoffski P, Sobrero A, Van Cutsem E, Diaz-Rubio E. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol. 2004 Jun 1;22(11):2084-91. doi: 10.1200/JCO.2004.11.069.
- Yoo PS, Lopez-Soler RI, Longo WE, Cha CH. Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab. Clin Colorectal Cancer. 2006 Sep;6(3):202-7. doi: 10.3816/CCC.2006.n.036.
- Lee WS, Yun SH, Chun HK, Lee WY, Yun HR, Kim J, Kim K, Shim YM. Pulmonary resection for metastases from colorectal cancer: prognostic factors and survival. Int J Colorectal Dis. 2007 Jun;22(6):699-704. doi: 10.1007/s00384-006-0218-2. Epub 2006 Nov 16.
- Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, Levitt R, Rowland K, Nair S, Sargent DJ, Donohue JH. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol. 2005 Dec 20;23(36):9243-9. doi: 10.1200/JCO.2005.07.740. Epub 2005 Oct 17.
- Dawood O, Mahadevan A, Goodman KA. Stereotactic body radiation therapy for liver metastases. Eur J Cancer. 2009 Nov;45(17):2947-59. doi: 10.1016/j.ejca.2009.08.011. Epub 2009 Sep 19.
- Kemeny N. Management of liver metastases from colorectal cancer. Oncology (Williston Park). 2006 Sep;20(10):1161-76, 1179; discussion 1179-80, 1185-6.
- Andre T, Louvet C, Maindrault-Goebel F, Couteau C, Mabro M, Lotz JP, Gilles-Amar V, Krulik M, Carola E, Izrael V, de Gramont A. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer. 1999 Sep;35(9):1343-7. doi: 10.1016/s0959-8049(99)00150-1.
- Jager E, Heike M, Bernhard H, Klein O, Bernhard G, Lautz D, Michaelis J, Meyer zum Buschenfelde KH, Knuth A. Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. J Clin Oncol. 1996 Aug;14(8):2274-9. doi: 10.1200/JCO.1996.14.8.2274.
- Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Saltz L. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 2008 Apr 20;26(12):2006-12. doi: 10.1200/JCO.2007.14.9898.
- Petrelli N, Herrera L, Rustum Y, Burke P, Creaven P, Stulc J, Emrich LJ, Mittelman A. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol. 1987 Oct;5(10):1559-65. doi: 10.1200/JCO.1987.5.10.1559.
- Wolmark N, Rockette H, Fisher B, Wickerham DL, Redmond C, Fisher ER, Jones J, Mamounas EP, Ore L, Petrelli NJ, et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol. 1993 Oct;11(10):1879-87. doi: 10.1200/JCO.1993.11.10.1879.
- Porschen R, Arkenau HT, Kubicka S, Greil R, Seufferlein T, Freier W, Kretzschmar A, Graeven U, Grothey A, Hinke A, Schmiegel W, Schmoll HJ; AIO Colorectal Study Group. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol. 2007 Sep 20;25(27):4217-23. doi: 10.1200/JCO.2006.09.2684. Epub 2007 Jun 4.
- Sargent DJ, Kohne CH, Sanoff HK, Bot BM, Seymour MT, de Gramont A, Porschen R, Saltz LB, Rougier P, Tournigand C, Douillard JY, Stephens RJ, Grothey A, Goldberg RM. Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. J Clin Oncol. 2009 Apr 20;27(12):1948-55. doi: 10.1200/JCO.2008.20.2879. Epub 2009 Mar 2. Erratum In: J Clin Oncol. 2009 Jul 10;27(20):3410-1.
- Chibaudel B, Tournigand C, Andre T, de Gramont A. Therapeutic strategy in unresectable metastatic colorectal cancer. Ther Adv Med Oncol. 2012 Mar;4(2):75-89. doi: 10.1177/1758834011431592. Erratum In: Ther Adv Med Oncol. 2012 Nov; 4(6):347-8.
- Ohtsu A, Baba H, Sakata Y, Mitachi Y, Horikoshi N, Sugimachi K, Taguchi T. Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group. Br J Cancer. 2000 Jul;83(2):141-5. doi: 10.1054/bjoc.2000.1236.
- Shirao K, Ohtsu A, Takada H, Mitachi Y, Hirakawa K, Horikoshi N, Okamura T, Hirata K, Saitoh S, Isomoto H, Satoh A. Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma. Cancer. 2004 Jun 1;100(11):2355-61. doi: 10.1002/cncr.20277.
- Jeung HC, Rha SY, Cho BC, Yoo NC, Roh JK, Roh WJ, Chung HC, Ahn JB. A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens. Br J Cancer. 2006 Dec 18;95(12):1637-41. doi: 10.1038/sj.bjc.6603468. Epub 2006 Nov 14.
- Lee DJ, Lee J, Lee HY, Lim T, Lee SJ, Yi SY, Park SH, Park JO, Lim HY, Kang WK, Park YS. Salvage S-1 monotherapy in metastatic colorectal cancer patients who failed irinotecan-based or oxaliplatin-based chemotherapy. Med Oncol. 2011 Dec;28 Suppl 1:S291-4. doi: 10.1007/s12032-010-9755-1. Epub 2010 Nov 30.
- Yamada Y, Tahara M, Miya T, Satoh T, Shirao K, Shimada Y, Ohtsu A, Sasaki Y, Tanigawara Y. Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer. Br J Cancer. 2008 Mar 25;98(6):1034-8. doi: 10.1038/sj.bjc.6604271. Epub 2008 Mar 4.
- Kim SY, Hong YS, Kim BC, Park JW, Choi HS, Jeong SY, Kim DY, Hong CW, Sohn DK, Jung KH. A phase II study of S-1 plus irinotecan and oxaliplatin in heavily-treated patients with metastatic colorectal cancer. Invest New Drugs. 2009 Jun;27(3):269-74. doi: 10.1007/s10637-008-9177-5. Epub 2008 Sep 25.
- Muro K, Boku N, Shimada Y, Tsuji A, Sameshima S, Baba H, Satoh T, Denda T, Ina K, Nishina T, Yamaguchi K, Takiuchi H, Esaki T, Tokunaga S, Kuwano H, Komatsu Y, Watanabe M, Hyodo I, Morita S, Sugihara K. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol. 2010 Sep;11(9):853-60. doi: 10.1016/S1470-2045(10)70181-9. Epub 2010 Aug 12.
- Hong YS, Park YS, Lim HY, Lee J, Kim TW, Kim KP, Kim SY, Baek JY, Kim JH, Lee KW, Chung IJ, Cho SH, Lee KH, Shin SJ, Kang HJ, Shin DB, Jo SJ, Lee JW. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial. Lancet Oncol. 2012 Nov;13(11):1125-32. doi: 10.1016/S1470-2045(12)70363-7. Epub 2012 Oct 10.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Sykdommer i fordøyelsessystemet
- Neoplasmer
- Neoplasmer etter nettsted
- Gastrointestinale neoplasmer
- Neoplasmer i fordøyelsessystemet
- Gastrointestinale sykdommer
- Kolonsykdommer
- Tarmsykdommer
- Intestinale neoplasmer
- Rektale sykdommer
- Kolorektale neoplasmer
- Fysiologiske effekter av legemidler
- Beskyttende agenter
- Mikronæringsstoffer
- Vitaminer
- Motgift
- Vitamin B kompleks
- Leucovorin
Andre studie-ID-numre
- TG1307
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Metastatisk tykktarmskreft
-
I-Mab Biopharma Co. Ltd.Ikke lenger tilgjengeligSolid Tumor Metastatic Cancer Advanced Cancer
-
AmgenAktiv, ikke rekrutterendeKRAS p, G12c Mutated /Advanced Metastatic NSCLCFinland, Forente stater, Canada, Belgia, Spania, Korea, Republikken, Nederland, Storbritannia, Australia, Danmark, Ungarn, Sverige, Taiwan, Hellas, Den russiske føderasjonen, Sveits, Frankrike, Italia, Japan, Polen, Brasil, Tyskland, ...
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeMetastatisk kolorektalt karsinom | Trinn IV tykktarmskreft AJCC v8 | Stage IVA tykktarmskreft AJCC v8 | Stage IVB tykktarmskreft AJCC v8 | Stage IVC Colorectal Cancer AJCC v8Forente stater
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)FullførtTrinn IV tykktarmskreft AJCC v7 | Stage IVA kolorektal kreft AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Kolorektalt adenokarsinom | RAS Wild TypeForente stater
-
University of California, San FranciscoMerck Sharp & Dohme LLCFullførtTrinn IV tykktarmskreft AJCC v7 | Stage IVA kolorektal kreft AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Mikrosatellitt stabil | Trinn III tykktarmskreft AJCC v7 | Trinn IIIB tykktarmskreft AJCC v7 | Stage IIIC tykktarmskreft AJCC v7 | Mismatch Repair Protein dyktigForente stater
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)FullførtTrinn IV tykktarmskreft AJCC v7 | Stage IVA kolorektal kreft AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Tilbakevendende kolorektalt karsinom | Metastatisk karsinom i leverenForente stater
-
Ning JinAktiv, ikke rekrutterendeMetastatisk kolorektalt karsinom | Trinn IV tykktarmskreft AJCC v8 | Stage IVA tykktarmskreft AJCC v8 | Stage IVB tykktarmskreft AJCC v8 | Stage IVC Colorectal Cancer AJCC v8Forente stater
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)FullførtTrinn IV tykktarmskreft AJCC v7 | Stage IVA kolorektal kreft AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatisk karsinom i leveren | Resektabel masseForente stater
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); Genentech, Inc.Aktiv, ikke rekrutterendeTrinn IV tykktarmskreft AJCC v7 | Stage IVA kolorektal kreft AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatisk malignt fast neoplasma | Ikke-opererbar fast neoplasma | BRAF NP_004324.2:p.V600X | KRAS wt AllelForente stater
-
M.D. Anderson Cancer CenterRekrutteringMetastatisk malign neoplasma i leveren | Metastatisk kolorektalt karsinom | Trinn IV tykktarmskreft AJCC v8 | Stage IVA tykktarmskreft AJCC v8 | Stage IVB tykktarmskreft AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Resektabelt kolorektalt karsinomForente stater
Kliniske studier på S-1+leucovorin
-
Tomoshi TsuchiyaFullført
-
Fudan UniversityThe First Affiliated Hospital of Anhui Medical University; Guangdong Provincial... og andre samarbeidspartnereTilbaketrukket
-
Zhejiang Cancer HospitalFullført
-
Peking University Cancer Hospital & InstituteRekruttering
-
Hamamatsu UniversityUkjentMagekreft | Bukspyttkjertelkreft | Kreft i spiserøret | TykktarmskreftJapan
-
Taiho Oncology, Inc.Quintiles, Inc.; United BioSource, LLCFullførtLokalt avansert eller metastatisk bukspyttkjertelkreft
-
TTY BiopharmNational Taiwan University Hospital; Chang Gung Memorial Hospital; Taipei... og andre samarbeidspartnereAvsluttetBukspyttkjertelkreft | Adjuvant kjemoterapi | Resekert bukspyttkjertelkreftTaiwan
-
Fudan UniversityFullførtNasofaryngealt karsinomKina
-
Seoul National University Bundang HospitalUkjent
-
Japan Clinical Cancer Research OrganizationKitasato UniversityFullført